Amgen Stock Surges Past $425 Amid Q2 Earnings Beat, Raised Guidance
Amgen stock continued its strong performance in August 2026, reaching $425.76 on Nasdaq after a solid second-quarter earnings beat and raised full-year guidance.
The biopharmaceutical company reported revenue of $10,054 million for Q2 2026, representing a 9.5 percent increase compared to the prior year period, with net income of $2,375 million and earnings per share of $6.29 beating consensus estimates by $0.67.
Amgen's full-year guidance for 2026 was raised to a range of $38.20 billion to $39.40 billion in revenue and $22.30 to $23.50 in GAAP EPS, with the company maintaining its position as a leader in the biotech industry with a diversified portfolio of therapies.
The stock's price-to-earnings ratio stands at 26.05, while the dividend yield is 2.34 percent, providing investors with a mix of income and growth opportunities.